Theseus Prescribed drugs, which aimed to beat the resistance that cancers develop to medicine, is shedding most of its workers and exploring options that might result in offers that eke out some worth from the corporate’s remaining property.
The announcement after Monday’s market shut come 4 months after early scientific knowledge for Theseus’s lead program confirmed dose-limiting toxicities in two out of six sufferers. The discovering led Cambridge, Massachusetts-based to discontinue that program.
Theseus has different packages and money to help them. As of the top of the second quarter of this 12 months, Theseus reported its money place was $234 million, which the corporate estimated would final into 2026. On the finish of September, Theseus mentioned its money place was $225.4 million.
Although Theseus beforehand said plans to additional develop its pipeline, it has since reconsidered. On Nov. 6, Theseus determined to put off 26 workers, representing about 72% of its workers, the corporate mentioned in a Monday regulatory filing. The layoffs will result in $5.5 million in severance prices, which the corporate expects will likely be incurred within the present quarter.
Amongst these dropping a job is William C. Shakespeare, the biotech’s president of analysis and growth. Theseus mentioned Shakespeare will proceed in a consultative function till June 30, 2024. The corporate additionally mentioned it plans to think about “a variety of choices with a concentrate on maximizing shareholder worth.” These strategic options might embrace a sale of the corporate, a merger with one other enterprise, or another transaction, Theseus mentioned.
Theseus’s former lead drug candidate, THE-360, was developed to deal with gastrointestinal stromal tumor (GIST), a sort of intestine most cancers pushed by mutations to the KIT gene that result in mutated types of the KIT kinase. Medicine from the category of medicines referred to as tyrosine kinase inhibitors can be found as first- and second-line therapies for GIST, however drug resistance is an ongoing drawback. Theseus aimed to beat resistance by creating “pan-variant” tyrosine kinase inhibitors supposed to focus on the primary cancer-causing and drug-resistance mutations. THE-360 was designed to deal with the varied mutations of the KIT kinase.
With the discontinuation of THE-360, Theseus shifted focus to THE-349, a tyrosine kinase inhibitor designed to focus on mutated variations of a most cancers protein referred to as EGFR. Developed as a possible therapy for EGFR mutant non-small cell lung most cancers, Theseus said in its report of second quarter financial results that it deliberate to submit an investigational new drug software for the molecule within the fourth quarter of this 12 months. The corporate additionally indicated it supposed to appoint extra drug candidates, together with one other pan-variant KIT inhibitor for GIST.
Theseus was incubated by OrbiMed and revealed its strategy to most cancers in 2021, backed by a $100 million Collection B financing. Months later, the corporate accomplished its IPO, pricing shares at $16 apiece and elevating $160 million. On Tuesday, shares of Theseus opened at $3.05, up 42.5% from Monday’s closing worth.
Picture: Getty Pictures